Collaboration to Develop Tumour Progression Regulator Leads

UK-based biopharmaceutical company Phoremost and AI driven pharmatech XtalPi, have signed an agreement to identify and develop compounds to advance a drug discovery program against targets that epigenetically regulate tumour progression and which have been previously classified as ‘undruggable’. The companies will pursue this challenging goal with a unique combination of machine learning and physics-based computation methods, using XtalPi’s intelligent digital drug discovery and development (ID4) platform, to explore novel sites discovered by PhoreMost’s SITESEEKER® platform.

“XtalPi’s AI-based ID4 and PhoreMost’s SITESEEKER are highly complementary platforms, and we look forward to working together with the team. This alliance marks an exciting chapter in PhoreMost’s development, as we now seek to rapidly progress our internal portfolio of novel first-in-class targets into drug discovery,” said Phoremost CEO Dr Chris Torrance.
“Today, many diseases lack effective treatment because their corresponding targets are too challenging for traditional drug discovery methods.,” added Dr Jian Ma, co-founder and CEO of XtalPi. “We are excited to combine PhoreMost’s target discovery technology with our ability to quickly identify lead compounds with desirable drug properties, and continuously translate high-quality ‘undruggable’ targets into first-in-class pipeline assets to address unmet medical needs.